Liminatus Pharma transfers to Nasdaq Capital Market, gets bid-price extension
Liminatus Pharma (LIMN) announces its transfer to the Nasdaq Capital Market and an extension aimed at regaining compliance with the Nasdaq minimum bid price requirement.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.